(trans-4-Phenylcyclohexyl)acetic acid | 52092-29-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (trans-4-Phenylcyclohexyl)acetic acid
• 英文别名: (trans)-2-(4-phenylcyclohexyl)acetic acid；trans-4-phenylcyclohexylacetic acid；(trans-4-phenyl-cyclohexyl)-acetic acid；(trans-4-Phenyl-cyclohexyl)-essigsaeure；trans-4-Phenyl-cyclohexylessigsaeure；trans-4-Phenylcyclohexylessigsaeure
• CAS: 52092-29-2
• 化学式: C₁₄H₁₈O₂
• 分子量: 218.296
• InChiKey: PBYZBGVGPMEGRS-AULYBMBSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.44
• 重原子数：
  16.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  37.3
• 氢给体数：
  1.0
• 氢受体数：
  1.0

反应信息

• 作为反应物：
  描述：

  (trans-4-Phenylcyclohexyl)acetic acid 在 乙醇 、 铂 作用下， 生成 (trans-bicyclohexylyl-(4))-acetic acid methyl ester
  参考文献：
  名称：

  Fieser et al., Journal of the American Chemical Society, 1948, vol. 70, p. 3177

  摘要：

  DOI：
• 作为产物：
  描述：

  (+/-)-(3-oxo-4t-phenyl-cyclohex-r-yl)-acetic acid 在 氢氧化钾 、 一水合肼 、 二乙二醇 作用下， 生成 (trans-4-Phenylcyclohexyl)acetic acid
  参考文献：
  名称：

  Experiments in the 4-Phenyl-2-cycloalkenone Series. Part I. Synthesis of 2,9-Diketo-1,2,3,4,4a,9,10,10a-octahydrophenanthrene

  摘要：

  DOI：

  10.1021/ja01109a053

文献信息

• [EN] IMMUNOREGULATORY AGENTS<br/>[FR] AGENTS IMMUNORÉGULATEURS
  申请人：FLEXUS BIOSCIENCES INC

  公开号：WO2015188085A1

  公开（公告）日：2015-12-10

  Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.

  本文描述了调节氧化还原酶酶类色氨酸2,3-二氧化酶的化合物，以及含有这些化合物的组合物。还提供了利用这些化合物和组合物治疗和/或预防多种由色氨酸2,3-二氧化酶介导的疾病、紊乱和症状，包括癌症和免疫相关紊乱的用途。
• Oxadiazole Derivative as Dgat Inhibitors
  申请人：Birch Martin Alan

  公开号：US20080096874A1

  公开（公告）日：2008-04-24

  Compounds of formula (I), and salts and pro-drugs thereof: Formula (I) wherein for example R 1 is optionally substituted aryl or heteroaryl; Y is a linking group selected from, for example, a direct bond, and a (substituted) alkyl chain; R 2 is an optionally substituted aryl, an optionally substituted cycloalkyl or an optionally substituted heterocyclic group; are described. Processes to make such compounds and their use as DGAT inhibitors, for example in the treatment of obesity, are also described.

  式（I）的化合物，以及其盐和前药：其中，例如R1是可选取代芳基或杂环芳基；Y是选择自直接键和（取代）烷基链等的连接基；R2是可选取代芳基、可选取代环烷基或可选取代杂环基团。还描述了制备此类化合物的方法及其作为DGAT抑制剂的用途，例如在肥胖症的治疗中。
• OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS
  申请人：BIRCH Alan Martin

  公开号：US20100317653A1

  公开（公告）日：2010-12-16

  Compounds of formula (I), and salts and pro-drugs thereof: wherein for example R 1 is optionally substituted aryl or heteroaryl; Y is a linking group selected from, for example, a direct bond, and a (substituted) alkyl chain; R 2 is an optionally substituted aryl, an optionally substituted cycloalkyl or an optionally substituted heterocyclic group; are described. Processes to make such compounds and their use as DGAT inhibitors, for example in the treatment of obesity, are also described.

  公式（I）的化合物、其盐和前药：其中，例如，R1是可选取代芳基或杂环芳基；Y是选自直接键和（取代）烷基链的连接基；R2是可选取代芳基、可选取代环烷基或可选取代杂环基团。本文描述了制备这种化合物的过程，以及它们作为DGAT抑制剂的用途，例如用于治疗肥胖症。
• Immunoregulatory agents
  申请人：FLEXUS BIOSCIENCES, INC.

  公开号：US10987322B2

  公开（公告）日：2021-04-27

  Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.

  本文描述了调节氧化还原酶吲哚胺 2,3-二氧化酶的化合物以及含有这些化合物的组合物。还提供了此类化合物和组合物用于治疗和/或预防由吲哚胺 2,3-二氧化酶介导的各种疾病、失调和病症，包括癌症和免疫相关失调。
• A novel approach to pH-Responsive targeted cancer Therapy: Inhibition of FaDu cancer cell proliferation with a pH low insertion Peptide-Conjugated DGAT1 inhibitor
  作者：Marine Deskeuvre、Junjie Lan、Joris Messens、Olivier Riant、Olivier Feron、Raphaël Frédérick

  DOI：10.1016/j.ijpharm.2024.124132

  日期：2024.5

  (pHLIP)-drug conjugate designed to selectively deliver DGAT1 inhibitors to cancer cells nested within the acidic microenvironment of tumors. We utilized two previously established pHLIP sequences for coupling with drugs. The study of DGAT1 conjugates in large unilamellar vesicles (LUVs) of different compositions did not reveal enhanced pH-dependent insertion compared to POPC LUVs. However, using 3D tumor spheroids

  靶向参与脂质代谢的酶越来越被认为是一种有前途的抗癌策略。有效抑制二酰基甘油 O-转移酶 1 (DGAT1) 可阻止脂肪酸 (FA) 储存。这反过来又会引发游离多不饱和 FA 浓度的增加，导致过氧化和铁死亡。在这项研究中，我们报告了 pH 敏感肽 (pHLIP)-药物缀合物的开发，该缀合物旨在选择性地将 DGAT1 抑制剂递送至肿瘤酸性微环境中的癌细胞。我们利用两个先前建立的 pHLIP 序列与药物偶联。对不同成分的大单层囊泡 (LUV) 中 DGAT1 缀合物的研究并未显示与 POPC LUV 相比，pH 依赖性插入增强。然而，使用 3D 肿瘤球体，在暴露于 pHLIP-T863（DGAT1 抑制剂）缀合物后观察到显着的抗增殖作用，超过了单独的 T863 的抑制活性。总之，我们的研究提供了第一个证据，证明基于 pHLIP 的 DGAT1 抑制剂缀合物有可能特异性靶向肿瘤的酸性区室。此外，它揭示了